Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men

Oxidative Medicine and Cellular Longevity

Volumn 3, Issue 4, 2010, Pages 262-265

  Tahara, Nobuhiro ^a   Imaizumi, Tsutomu ^a   Takeuchi, Masayoshi ^b   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; Insulin resistance; Testosterone

Indexed keywords

ADVANCED GLYCATION END PRODUCTS; AGES; BLOOD CHEMISTRY; CARDIO-VASCULAR DISEASE; DYSLIPIDEMIAS; HOMEOSTASIS MODEL ASSESSMENTS; INSULIN RESISTANCE; METABOLIC VARIABLES; MULTIPLE STEPWISE REGRESSION; PLASMA GLUCOSE; SERUM LEVELS; TESTOSTERONE; UNIVARIATE ANALYSIS; URIC ACIDS;

BLOOD; BLOOD PRESSURE; GLUCOSE; ORGANIC ACIDS; REGRESSION ANALYSIS;

INSULIN;

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL; URIC ACID;

ARTICLE; BLOOD CHEMISTRY; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHYSICAL EXAMINATION; SMOKING; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; WAIST CIRCUMFERENCE; ADULT; AGED; BLOOD; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS; TESTOSTERONE;

EID: 77957366321     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.4161/oxim.3.4.12734     Document Type: Article

References (29)

1. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic and clinical implications for diabetes and aging. Lab Invest 1994; 70:138-51.
2. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995; 46:223-34.
3. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11:2279-99. (Pubitemid 40872698)
4. Yamagishi S, Matsui T. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Curr Drug Targets 2010; 11:875-81.
5. Yamagishi S, Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010; 3:1-8.
6. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008; 17:983-96.
7. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis 2009; 16:845-58.
8. Hyogo H, Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008; 14:969-72. (Pubitemid 351753284)
9. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008; 14:940-5.
10. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009; 5:673-81.
11. Yeap BB. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 2009; 5:113-21.
12. Kapoor D, Jones TH. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging 2008; 25:357-69.
13. Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res 2009; 21:24-36.
14. Francomano D, Bruzziches R, Natali M, Aversa A, Spera G. Cardiovascular effect of testosterone replacement therapy in aging male. Acta Biomed 2010; 81:101-6.
15. Hernández-Mijares A, García-Malpartida K, Solá- Izquierdo E, Bañuls C, Rocha M. Testosterone Levels in Males with Type 2 Diabetes and Their Relationship with Cardiovascular Risk Factors and Cardiovascular Disease. J Sex Med 2010; In press.
16. Chandel A, Dhindsa S, Topiwala S, Chaudhuri A, Dandona P. Testosterone concentration in young patients with diabetes. Diabetes Care 2008; 31:2013-7.
17. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7:463-9.
18. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2009; 385:269-72.
19. Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009; 60:174-8.
20. Li H, Zheng X, Wang H, Zhang Y, Xin H, Chen X. XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products. Eur J Pharmacol 2010; 627:340-7.
21. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Janswlwit-Dahm KA, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53:1813-23.
22. Panagiotopoulos S, O'Brien RC, Bucala R, Cooper ME, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998; 136:125-31. (Pubitemid 28341449)
23. Nakamura Y, Horii Y, Nishino T, Shiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 43:1649-56.
24. Barlovic DP, Thomas MC, Jandeleit-Dahm K. Cardiovascular disease: what's all the AGE/RAGE about? Cardiovasc Hematol Disord Drug Targets 2010; 10:7-15.
25. Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K, Matsui T, et al. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 2007; 39:845-8.
26. Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005; 25:815-20.
27. Yamagishi S, Adachi H, Abe A, Yashiro T, Enomoto M, Furuki K, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006; 91:2447-50.
28. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22:1112-9.
29. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure. Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109:1004-9.